Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Wall st set to open higher as chip stocks gain; US-Iran tensions in focus
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil eases as investors assess US-Iran peace prospects
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
Jefferies Downgrades Aadi Bioscience Inc (AADI) to Hold
August 21, 2024 3:47 PM EDTJefferies analyst Roger Song downgraded Aadi Bioscience Inc (NASDAQ: AADI) from Buy to Hold with a price target of $1.50 (from $11.00).
The analyst comments "We spoke w/ mgmt following IDMC demonstrated nab-sirolimus (mTOR) tumor agonostic pivotal in TSC1/TSC2 tumors was unlikely to... More
TD Cowen Downgrades Aadi Bioscience Inc (AADI) to Hold
August 21, 2024 4:47 AM EDTTD Cowen analyst Boris Peaker downgraded Aadi Bioscience Inc (NASDAQ: AADI) from Buy to Hold.
The analyst comments "Aadi management announced that the PRECISION1 trial in TSC1/2 solid tumors will be discontinued due to low probability of meeting the efficacy threshold needed for accelerated... More
